HER2 in Genitourinary Cancers: Clinical Relevance and Real-World Testing Considerations

from Medical News Podcast · host PeerDirect Publishing

Drs. Mantia and Berg discuss HER2 as a biomarker in genitourinary cancers, focusing on testing strategies, prevalence, and the clinical implications of HER2 expression and ERBB2 mutations for patient management. They also review new data from ESMO 2025, highlighting the DISTINCT-1 trial and a HER2-targeted approach for high-risk upper tract genitourinary carcinoma.

Episode metadata supplied by the publisher feed · Published May 1, 2026

Embed this episode

Attribution link and audio player

NOW PLAYING

HER2 in Genitourinary Cancers: Clinical Relevance and Real-World Testing Considerations

0:00 11:14

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Medical News Podcast?

This episode is 11 minutes long.

When was this Medical News Podcast episode published?

This episode was published on May 1, 2026.

Can I download this Medical News Podcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!